A BILL 
To establish the National Patient Safety Board. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘National Patient Safe-
4
ty Board Act of 2022’’. 
5
SEC. 2. NATIONAL PATIENT SAFETY BOARD. 
6
(a) ESTABLISHMENT.—There is hereby established 
7
an independent agency to be known at the National Pa-
8
tient Safety Board (in this section referred to as the 
9
21:32 Dec 05, 2022
H9377
2 
•HR 9377 IH
‘‘Board’’) for the purpose of preventing and reducing pa-
1
tient safety events. 
2
(b) DUTIES.— 
3
(1) IN GENERAL.—For the purpose stated in 
4
subsection (a), the Board shall— 
5
(A) support Federal departments and 
6
agencies in monitoring and anticipating patient 
7
safety events with patient safety data surveil-
8
lance technologies; 
9
(B) provide expertise to study the context 
10
and causes of patient safety events and solu-
11
tions; and 
12
(C) formulate recommendations and solu-
13
tions to prevent patient safety events from oc-
14
curring. 
15
(2) ANNUAL AUDIT.—The Board shall undergo 
16
an annual audit. 
17
(3) ANNUAL REPORTS TO CONGRESS.— 
18
(A) SUBMISSION.—The Chair of the Board 
19
shall submit annual reports to the Congress on 
20
the progress of the Board in achieving the pur-
21
pose stated in subsection (a). 
22
(B) 
CONTENTS.—Each 
annual 
report 
23
under subparagraph (A) shall include— 
24
21:32 Dec 05, 2022
H9377
3 
•HR 9377 IH
(i) input from the director of each di-
1
vision of the Board; 
2
(ii) detailed solutions; 
3
(iii) unaddressed needs; and 
4
(iv) any other information determined 
5
by the Chair of the Board to be relevant 
6
to achieving the purpose stated in sub-
7
section (a). 
8
(c) HEARINGS; REPORTS.— 
9
(1) IN GENERAL.—The Board may, for the pur-
10
pose of carrying out this Act, hold hearings, sit and 
11
act at times and places, take testimony, receive evi-
12
dence, and issue such reports as the Board considers 
13
appropriate. 
14
(2) NO INDIVIDUALLY IDENTIFIABLE INFORMA-
15
TION IN PUBLICATIONS.—The Board (including any 
16
division, subdivision, or other component thereof) 
17
shall not include in any report or other publication 
18
information that can be used to identify any patient, 
19
health care provider, or health care setting. 
20
(d) MEMBERSHIP.— 
21
(1) IN
GENERAL.—The Board shall be com-
22
posed of 5 members, each nominated— 
23
(A) by the President, by and with the ad-
24
vice and consent to the Senate; and 
25
21:32 Dec 05, 2022
H9377
4 
•HR 9377 IH
(B) for a term of 6 years. 
1
(2) CHAIR; VICE CHAIR.—The Board shall have 
2
a Chair and Vice Chair who shall each— 
3
(A) be designated by the President from 
4
among the members of the Board appointed 
5
under paragraph (1); and 
6
(B) serve for a 3-year term. 
7
(e) STAFFING.—The Chair of the Board may appoint 
8
such personnel as the Chair considers appropriate to carry 
9
out this section. 
10
(f) ORGANIZATION.—The Board shall have— 
11
(1) an Office of the Chair of the Board; 
12
(2) a Patient Safety Event Monitoring Division, 
13
to be headed by a director appointed by the Board; 
14
(3) a Study Division, to be headed by a director 
15
appointed by the Board; 
16
(4) a Patient Safety Solutions Division, to be 
17
headed by a director appointed by the Board; 
18
(5) an Administrative Division, to be headed by 
19
a director appointed by the Board; and 
20
(6) regional offices. 
21
(g) PATIENT SAFETY EVENT MONITORING DIVI-
22
SION.— 
23
(1) HEALTH CARE SAFETY TEAM.— 
24
21:32 Dec 05, 2022
H9377
5 
•HR 9377 IH
(A) IN GENERAL.—For the purpose stated 
1
in subsection (a), the Director of the Patient 
2
Safety Event Monitoring Division shall estab-
3
lish and maintain a public-private team, to be 
4
known as a Health Care Safety Team, to re-
5
view, update, and prioritize patient safety event 
6
measures and data sources related to patient 
7
and provider safety in health care settings, in-
8
cluding survey data, electronic health records 
9
data, claims data, health information exchange 
10
data, and reports of patient safety events. 
11
(B) 
RECOMMENDATIONS.—The 
Health 
12
Care Safety Team shall recommend to public 
13
and private entities patient safety data surveil-
14
lance technologies and specifications with the 
15
ability to identify and anticipate the patient 
16
safety measures. 
17
(C) MEMBERSHIP.—The membership of 
18
the Health Care Safety Team under subpara-
19
graph (A) shall include— 
20
(i) representatives with patient safety 
21
expertise from the following Federal agen-
22
cies: the Agency for Healthcare Research 
23
and Quality, the Centers for Disease Con-
24
trol and Prevention, the Centers for Medi-
25
21:32 Dec 05, 2022
H9377
6 
•HR 9377 IH
care & Medicaid, the Department of Vet-
1
erans Affairs, the Office of the National 
2
Coordinator for Health Information Tech-
3
nology, the Indian Health Service, the Of-
4
fice of Minority Health of the Department 
5
of Health and Human Services, the Health 
6
Resources and Services Administration, the 
7
Substance Abuse and Mental Health Serv-
8
ices Administration, the Food and Drug 
9
Administration, the National Institutes of 
10
Health, and the United States Preventive 
11
Services Task Force; and 
12
(ii) representatives of the private sec-
13
tor with patient safety expertise, rep-
14
resenting providers, organized labor, health 
15
care organizations, patients, payors, sup-
16
pliers, vendors, manufacturers, measure-
17
ment developers, and data technology ex-
18
perts. 
19
(2) OBTAINING OFFICIAL DATA.—To carry out 
20
this subsection, the Director of the Patient Safety 
21
Event Monitoring Division may secure directly from 
22
any office or agency of the Department of Health 
23
and Human Services or the Department of Veterans 
24
Affairs longitudinal, real-time, de-identified patient 
25
21:32 Dec 05, 2022
H9377
7 
•HR 9377 IH
data, disaggregated by race, ethnicity, gender, facil-
1
ity, and location, relating to patient safety event 
2
measures. Upon request of the Director of the Pa-
3
tient Safety Event Monitoring Division, the head of 
4
the respective office or agency shall furnish that 
5
data to the Director. The Director shall maintain 
6
and use such data consistent with applicable privacy 
7
and confidentiality law. 
8
(3) WEBSITE OR SYSTEM.—The Director of the 
9
Patient Safety Event Monitoring Division shall cre-
10
ate and maintain a website or system, to be known 
11
as the Patient Safety Reporting System, that can be 
12
used by patients, health care providers, non-clinical 
13
staff, or any other person to report patient safety 
14
events to the Division. 
15
(4) DATA
ACCESS
16
the Patient Safety Event Monitoring Division 
17
shall— 
18
(A) enter into agreements with public and 
19
private entities, including at the State and local 
20
levels, to opt into allowing the Division to ac-
21
cess the entity’s longitudinal, real-time, de-iden-
22
tified patient data, disaggregated by race, eth-
23
nicity, gender, facility, and location, relating to 
24
patient safety event measures; 
25
21:32 Dec 05, 2022
H9377
8 
•HR 9377 IH
(B) maintain a data access portal to enable 
1
such entities to submit such data to the Divi-
2
sion; and 
3
(C) maintain and use such data consistent 
4
with applicable privacy and confidentiality law. 
5
(5) REPORTING.—The Director of the Patient 
6
Safety Event Monitoring Division shall— 
7
(A) submit to the Health Care Safety 
8
Team maintained under paragraph (1) regular 
9
reports on patient safety event surveillance; and 
10
(B) prompt the Study Division when any 
11
of the following types of findings are identified 
12
in a geographic area or health care organiza-
13
tion: 
14
(i) The most frequently occurring 
15
major sources of patient safety events. 
16
(ii) Abnormal patterns of patient safe-
17
ty events. 
18
(iii) Unexpectedly low numbers of pa-
19
tient safety events. 
20
(iv) Racial, ethnic, social, gender, or 
21
geographic disparities. 
22
(v) Unaddressed reoccurring patient 
23
safety events. 
24
(h) STUDY DIVISION.— 
25
21:32 Dec 05, 2022
H9377
9 
•HR 9377 IH
(1) IN GENERAL.—The Director of the Study 
1
Division may conduct or support studies with re-
2
spect to patient safety events, including to under-
3
stand the— 
4
(A) circumstances, context, and conditions 
5
that enable patient safety events; and 
6
(B) causes or probable causes of the high 
7
or low number of patient safety events. 
8
(2) DATA SHARING.— 
9
(A) REQUEST.—In conducting or sup-
10
porting a study under paragraph (1), the Direc-
11
tor of the Study Division may request from the 
12
Director of the Patient Safety Event Moni-
13
toring Division such information as may be col-
14
lected by the Patient Safety Event Monitoring 
15
Division and relevant to the study. 
16
(B) SHARING.—Upon receipt of such a re-
17
quest, the Director of the Patient Safety Event 
18
Monitoring Division shall share such informa-
19
tion with the Director of the Study Division. 
20
(3) STUDY REQUIREMENTS.—In conducting or 
21
supporting a study under paragraph (1): 
22
(A) STUDY
LEAD.—The Director of the 
23
Study Division shall— 
24
21:32 Dec 05, 2022
H9377
10 
•HR 9377 IH
(i) appoint an individual to serve as 
1
the person in charge of the study (in this 
2
paragraph referred to as the ‘‘Study 
3
Lead’’); and 
4
(ii) vest such person with authority to 
5
determine the appropriate type of study, 
6
assemble a study team of experts, identify 
7
the study site or sites, and ask any health 
8
care organization that experienced the un-
9
expectedly high or low numbers of patient 
10
safety events for permission to conduct the 
11
study based on prompts from the Patient 
12
Safety Event Monitoring Division. 
13
(B) STUDY
TEAM.—The Study Lead 
14
shall— 
15
(i) assemble a team of multidisci-
16
plinary experts to improve the under-
17
standing of high or low numbers of patient 
18
safety events in the context of the study, 
19
including by gathering qualitative and 
20
quantitative information to understand— 
21
(I) the circumstances, context, 
22
and conditions that enable the patient 
23
safety events; and 
24
21:32 Dec 05, 2022
H9377
11 
•HR 9377 IH
(II) 
the 
causes 
or 
probable 
1
causes of the high or low number pa-
2
tient safety events; 
3
(ii) include in such team individuals 
4
with the ability to study and understand 
5
the interaction of human abilities, expecta-
6
tions, and limitations with work environ-
7
ments, technologies, and system design and 
8
other appropriate experts from the public 
9
and private sectors; 
10
(iii) prohibit such team from releasing 
11
information obtained during the study 
12
prior to the public release of such informa-
13
tion by the National Patient Safety Board; 
14
and 
15
(iv) ensure that such team receives 
16
permission from each health care organiza-
17
tion involved to— 
18
(I) enter health care facilities 
19
participating in the study; and 
20
(II) 
communicate 
with 
staff, 
21
health care providers, patients, ven-
22
dors, suppliers, contractors, equip-
23
ment manufacturers, and members of 
24
the Board. 
25
21:32 Dec 05, 2022
H9377
12 
•HR 9377 IH
(C) APPROPRIATE TYPE OF STUDY.—The 
1
Director of the Study Division shall— 
2
(i) create guidelines and criteria to de-
3
termine the appropriate type of study to be 
4
conducted or supported, including whether 
5
the study should be virtual, in-person, or a 
6
special board of inquiry; and 
7
(ii) in creating such guidelines and 
8
criteria, take into account the impact of 
9
the patient safety events to be studied, 
10
whether such patient safety events may in-
11
dicate a systemic risk, and what may po-
12
tentially be learned from the study. 
13
(D) NOVEL INFECTION AND EMERGENCY 
14
PANDEMIC.—In the case of a novel infection 
15
and emerging pandemic, the Director of the 
16
Study Division may establish a special board of 
17
inquiry— 
18
(i) 
to 
provide 
independent 
rec-
19
ommendations on a coordinated national 
20
preparedness and response plan; 
21
(ii) to independently monitor the im-
22
plementation of the preparedness and re-
23
sponse plan; and 
24
21:32 Dec 05, 2022
H9377
13 
•HR 9377 IH
(iii) to recommend technologies to 
1
support logistics and autonomous real-time 
2
research to inform evidence-based treat-
3
ment options and decisions. 
4
(4) REPORTING.—The Director of the Study 
5
Division shall— 
6
(A) provide for the submission to the 
7
Board and the Patient Safety Solutions Divi-
8
sion of— 
9
(i) at least one progress report on 
10
each study under this subsection over the 
11
course of the study; and 
12
(ii) a final report upon the conclusion 
13
of the study; 
14
(B) include in a final report under sub-
15
paragraph (A)(ii) factual information and anal-
16
ysis regarding the probable causes of the high 
17
or low numbers of patient safety events being 
18
studied and the recommendations of the Patient 
19
Safety Solutions Division; and 
20
(C) make such final report publicly avail-
21
able. 
22
(5) RESPONSE BY BOARD.—Upon receipt of a 
23
final report under paragraph (4)(A)(ii), the Board 
24
may elect to— 
25
21:32 Dec 05, 2022
H9377
14 
•HR 9377 IH
(A) adopt the report; 
1
(B) work with the Study Division to make 
2
changes to the report prior to adoption; or 
3
(C) require the Study Division to conduct 
4
or support further studies or revisions. 
5
(6) TIMING.—The Director of the Study Divi-
6
sion shall ensure that, not later than 1 year after 
7
the commencement of a study under this section— 
8
(A) the study is completed; and 
9
(B) the final report is made publicly avail-
10
able pursuant to paragraph (4)(C). 
11
(7) LIMITATION
ON
AUTHORITY.—The Study 
12
Division and any study team established under this 
13
subsection shall not have authority to determine the 
14
rights or liabilities of any person with respect to ad-
15
verse patient safety events. 
16
(i) PATIENT SAFETY SOLUTIONS DIVISION.— 
17
(1) ANALYSIS.—Whenever the Director of the 
18
Study Division provides a final report on a study 
19
pursuant to subsection (h)(4), the Director of the 
20
Patient Safety Solutions Division shall— 
21
(A) analyze such report; and 
22
(B) formulate recommendations (including 
23
solutions) to prevent the patient safety events 
24
that were studied from occurring. 
25
21:32 Dec 05, 2022
H9377
15 
•HR 9377 IH
(2) WORKING
WITH
HEALTH
CARE
SAFETY 
1
TEAM.—In formulating recommendations (including 
2
solutions) under paragraph (1), the Director of the 
3
Patient Safety Event Monitoring Division shall— 
4
(A) in consultation with the Health Care 
5
Safety Team under subsection (g)(1), identify 
6
or develop solutions based on the causes of the 
7
patient safety events that were studied; and 
8
(B) include such solutions in the rec-
9
ommendations. 
10
(3) RESPONSE BY SECRETARY.—Not later than 
11
90 days after the submission of the final report 
12
under subsection (h)(4)(A)(ii), the Secretary of 
13
Health and Human Services and the Secretary of 
14
Veterans Affairs shall publish a response to the rec-
15
ommendations. 
16
(j) ADMINISTRATIVE DIVISION.— 
17
(1) IN GENERAL.—The Director of the Admin-
18
istrative Division shall support the day-to-day activi-
19
ties of the Board, including with respect to commu-
20
nications, facility coordination, shipping and receiv-
21
ing, supply inventory, labor relations, and human re-
22
source management. 
23
21:32 Dec 05, 2022
H9377
16 
•HR 9377 IH
(2) SUBDIVISION.—The Administrative Division 
1
shall have a Safety and Equity Subdivision which 
2
shall— 
3
(A) advise on, analyze, and publish proper 
4
safety guidelines to ensure safe working condi-
5
tions at the Federal, State, and local levels; 
6
(B) create an equity plan to ensure that 
7
the Board’s programs and operations take into 
8
consideration the implications of, and remedies 
9
to address, discrimination and disparities; and 
10
(C) provide training to enhance employee 
11
safety competence. 
12
(k) PROHIBITION AGAINST ADMISSIBILITY AS EVI-
13
DENCE.—Any report or other publication of the Board (in-
14
cluding any division, subdivision, or other component 
15
thereof) shall not be admissible as evidence, or used for 
16
any purpose, in any Federal or State action, suit, or other 
17
judicial, legislative, or administrative proceeding. 
18
(l) PROTECTIONS FOR EMPLOYEES.— 
19
(1) PROHIBITION.—No employer shall dis-
20
charge or in any manner discriminate against any 
21
employee with respect to compensation, terms, con-
22
ditions, or other privileges of employment because 
23
the employee (or an individual acting at the request 
24
of the employee)— 
25
21:32 Dec 05, 2022
H9377
17 
•HR 9377 IH
(A) has cooperated, or is perceived as 
1
being about to cooperate, with a study of the 
2
Board; or 
3
(B) has submitted a report to the Patient 
4
Safety Reporting System of the Patient Safety 
5
Event Monitoring Division. 
6
(2) COMPLAINT PROCEDURE.— 
7
(A) IN GENERAL.—An employee who be-
8
lieves that he or she has been discharged or 
9
otherwise discriminated against by any em-
10
ployer in violation of this subsection may seek 
11
relief in accordance with the procedures, notifi-
12
cations, burdens of proof, remedies, and stat-
13
utes of limitation set forth in section 2087(b) of 
14
title 15, United States Code. 
15
(B) NO LIMITATION ON RIGHTS.—Nothing 
16
in this subsection shall be deemed to diminish 
17
the rights, privileges, or remedies of any em-
18
ployee under any Federal or State law or under 
19
any collective bargaining agreement. The rights 
20
and remedies in this subsection may not be 
21
waived by any agreement, policy, form, or con-
22
dition of employment. 
23
(3) DEFINITION.—In this subsection, the term 
24
‘‘employer’’ has the meaning given to such term in 
25
21:32 Dec 05, 2022
H9377
18 
•HR 9377 IH
section 3 of the Fair Labor Standards Act of 1938 
1
(29 U.S.C. 203). 
2
(m) DEFINITIONS.—In this section: 
3
(1) The term ‘‘health care setting’’ means a 
4
hospital, nursing facility, comprehensive outpatient 
5
rehabilitation facility, home health agency, hospice 
6
program, renal dialysis facility, ambulatory surgical 
7
center, pharmacy, physician or other health care 
8
practitioner’s office, long-term care facility, mental 
9
health treatment facility, substance use disorder 
10
treatment facility, clinical laboratory, or health cen-
11
ter. 
12
(2) The term ‘‘patient safety event’’ means an 
13
action or inaction that— 
14
(A) led to patient injury or harm in a 
15
health care setting; 
16
(B) could lead to patient injury or harm as 
17
a precursor to injury or harm in a health care 
18
setting; or 
19
(C) could have caused injury or harm to 
20
the patient but did not cause injury or harm in 
21
a health care setting as a result of chance, pre-
22
vention, or mitigation. 
23
21:32 Dec 05, 2022
H9377
19 
•HR 9377 IH
(n) AUTHORIZATION OF APPROPRIATIONS.—To carry 
1
out this section, there is authorized to be appropriated 
2
$110,000,000 for each of fiscal years 2023 and 2024. 
3
Æ 
21:32 Dec 05, 2022
H9377
